The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data

BACKGROUND: Adebrelimab showed excellent efficacy in the first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, whether adebrelimab is superior to durvalumab and atezolizumab remains unclear. Therefore, we, in this study, aimed to compare the survival data of adebrelimab...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bi-Cheng, Fu, Chen, Lin, Guo-He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196127/
https://www.ncbi.nlm.nih.gov/pubmed/37215120
http://dx.doi.org/10.3389/fimmu.2023.1185577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196127/
https://www.ncbi.nlm.nih.gov/pubmed/37215120
http://dx.doi.org/10.3389/fimmu.2023.1185577

Ejemplares similares